Study Comparing Tapinarof Cream 1% To VTAMA ® (Tapinarof Cream 1%) In the Treatment of Plaque Psoriasis

NCT06742957 | Completed Phase 3 FDA Drug

• 1 other identifier: 72336004
• Study Type: interventional
• Target: 560
• Locations: 1 country
• Sites: 26

Brief Summary

To compare the safety and efficacy of the test (Tapinarof Cream 1%), placebo (vehicle cream) and reference VTAMA® (Tapinarof Cream 1%) treatments to demonstrate clinical equivalence in patients with plaque psoriasis.

Conditions

Plaque Type Psorisis

Keywords

Dermatologic Agents; Skin Diseases; Plaque Psoriasis; Tapinarof; Adult; Phase 3; Topical; Double-Blind; Safety; Efficacy; Skin Diseases, Papulosquamous

Outcome Measures

Primary Outcomes (1)

• Primary change in the Physician Global Assessment (PGA)

  Proportion of patients with treatment success (defined as a Physician Global Assessment (PGA) score of clear (0) or almost clear (1) with a minimum 2-grade improvement from baseline at the end of treatment (Week 12; Study Day 84): Score of (0) Clear: No signs of psoriasis; post-inflammatory hyperpigmentation may be present Score of (1) Almost Clear: No thickening; normal to pink coloration; no to minimal focal scaling Score of (2) Mild: Just detectable to mild thickening; pink to light red coloration; predominantly fine scaling Score of (3) Moderate: Clearly distinguishable to moderate thickening; dull to bright red, clearly distinguishable erythema; moderate scaling Score of (4) Severe: Severe thickening with hard edges; bright to deep dark red coloration; severe/coarse scaling covering almost all or all lesions

  12 Weeks

Study Arms (3)

Test: Tapinarof Cream 1%

EXPERIMENTAL

Tapinarof Cream 1%, Apply a thin layer once daily to psoriatic affected areas for 84 days.

Drug: Tapinarof Cream 1%

VTAMA®

ACTIVE COMPARATOR

(Tapinarof) Cream 1%, Apply a thin layer once daily to psoriatic affected areas for 84 days.

Drug: VTAMA®

Vehicle Product

PLACEBO COMPARATOR

Vehicle of the Test Product, Cream, Apply a thin layer once daily to psoriatic affected areas for 84 days.

Drug: Placebo

Interventions

Tapinarof Cream 1% DRUG

Cream

Test: Tapinarof Cream 1%

VTAMA® DRUG

Cream

VTAMA®

Placebo DRUG

Cream

Vehicle Product

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Signed ICF indicating that the patient understands the purpose of, and procedures required for the study and is willing to participate in the study.
• Males and non-pregnant, non-lactating females aged ≥18 at the time of signing the informed consent.
• Patients with clinical diagnosis of chronic plaque psoriasis and stable disease for at least 6 months prior to the study.
• Body surface area (BSA) involvement ≥ 3% and ≤ 20% (the patient's face, scalp, groins, palms and soles should be excluded from the percent of total BSA (%BSA) calculations).
• A Physician's Global Assessment (PGA) score of 2 (mild), 3 (moderate) or 4 (severe) at screening and baseline.
• Female patients of childbearing potential (\*WOCBP) must not be pregnant or lactating at the time of screening/baseline visit as documented by a negative urine pregnancy test with a sensitivity to at least 25 mIU/ml hCG:
• \*Female patients of childbearing potential (WOCBP) are defined as sexually mature women without prior hysterectomy, or who have had any evidence of menses in the past 12 months. However, women who have been amenorrheic for the past 12 or more months are still considered to be of childbearing potential, if the amenorrhea is possibly due to other causes, including prior chemotherapy, anti- estrogens, or ovarian suppression. Postmenopausal women (defined as women who have been amenorrheic for at least 12 consecutive months, in the appropriate age group, without other known or suspected primary cause) or women who have been sterilized surgically or who are otherwise proven sterile (i.e., total hysterectomy, or bilateral oophorectomy with surgery at least 4 weeks prior to randomization) are not considered WOCBP. Patients who have undergone tubal ligation are NOT considered as surgically sterile.
• Female patients of childbearing potential must be willing to use an acceptable form of birth control during the study from the day of the first dose administration to 30 days after the last administration of study drug.
• For the purposes of this study the following are considered acceptable methods of birth control: oral or injectable contraceptives, contraceptive patches, medroxyprogesterone acetate (ex. Depo-Provera®) with stabilized use for at least 3 months, vaginal contraceptive (ex. etonogestrel/ethinyl estradiol vaginal ring (ex. NuvaRing®), contraceptive implant with etonogestrel or equivalent, double barrier methods, (e.g. condom and spermicide), intrauterine device (IUD), true abstinence (if in line with patient's lifestyle).
• Patients on hormonal contraception must be stabilized on the same type for at least three months prior to enrollment in the study and must not change the method during the study. A sterile sexual partner is not considered an adequate form of birth control.
• If a patient who was abstinent becomes sexually active during the study, a second acceptable method of birth control should be used and documented.
• Willing and able to adhere to the lifestyle restrictions specified in this protocol.
• Patients must be in good health and free from any clinically significant disease, which may interfere with the evaluation of plaque psoriasis or the administration of the investigative product.
• Patients must be willing to refrain from using all other topical plaque psoriasis products during the 12-week treatment period, other than the investigational product.

You may not qualify if:

• Known allergies, hypersensitivity, or intolerance to any of the ingredients of study treatment interventions, or components/ excipients thereof (refer to the prescribing information of VTAMA®), or drug or other allergy that, in the opinion of the investigator, contraindicates participation in the study.
• Current diagnosis of unstable forms of psoriasis (other than plaque variant) in the treatment area, including guttate, erythrodermic, exfoliative or pustular psoriasis.
• Patients with other inflammatory skin disease in the treatment area that may confound the evaluation of the plaque psoriasis (e.g., atopic dermatitis, contact dermatitis, tinea corporis, and or any others in the opinion of the Investigator).
• Presence of pigmentation, extensive scarring, or pigmented lesions in the treatment areas, which could interfere with the rating of efficacy parameters.
• Patients with current immunosuppression.
• Ultraviolet (UV) light therapy or prolonged exposure to natural or artificial sources of UV radiation (eg, phototherapy, tanning booths, or therapeutic sunbathing), laser therapy, tattoos removal, skin wraps or exfoliant techniques or Fraxel within 4 weeks prior to the baseline visit and/or plans to have such exposures during the study which could potentially impact the patient's psoriasis (as determined by the Investigator).
• Use of biological treatments for psoriasis within the last 6 months of the baseline evaluation.
• Patients that have been treated with systemic steroids, systemic antibiotics, systemic anti-psoriatic treatment (i.e., methotrexate, cyclosporine, hydroxyurea), PUVA therapy, ultraviolet- B Therapy or systemic anti-inflammatory agents within 1 month or within 5 half-lives (whichever is longer) before Baseline.
• Use of any of the following therapies within two weeks prior to baseline:
• topical anti-psoriatic drugs (e.g., salicylic acid, anthralin, coal tar, calcipotriene, tazarotene)
• topical corticosteroids
• immunosuppressive drugs (e.g., tacrolimus, pimecrolimus)
• topical retinoids
• Received an investigational intervention within 30 days or 5 half-lives prior to the first dose of study intervention, whichever is longer.
• Documented medical history of uncontrolled, clinically significant intercurrent medical condition(s) (i.e., chronic infectious disease, system disorder, organ disorder, cardiovascular, gastrointestinal, hematological, hepatic, neurological, pancreatic, renal disease, severe psychiatric condition, etc.) for which, in the opinion of the investigator, participation would not be in the best interest of the patient (e.g., compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments.

Sponsors & Collaborators

• Teva Pharmaceuticals USA: lead
• Teva Pharmaceuticals, Inc.: collaborator

Study Sites (26)

Site 12107

Scottsdale, Arizona, 85260, United States

Location

Site 12101

Bryant, Arkansas, 72022, United States

Location

Site 12110

Dublin, California, 94568, United States

Location

Site 12112

Dublin, California, 94568, United States

Location

Site 12102

Fremont, California, 94538, United States

Location

Site 12119

Huntington Beach, California, 92647, United States

Location

Site 12120

Northridge, California, 91325, United States

Location

Site 12111

Pomona, California, 91767, United States

Location

Site 12122

Greenwich, Connecticut, 06831, United States

Location

Site 12115

Fort Lauderdale, Florida, 33308, United States

Location

Site 12104

Miami, Florida, 33144, United States

Location

Site 12116

Miami, Florida, 33146, United States

Location

Site 12113

Miami, Florida, 33175, United States

Location

Site 12114

Miramar, Florida, 33027, United States

Location

Site 12108

Chicago, Illinois, 60614, United States

Location

Site 12121

Rolling Meadows, Illinois, 60008, United States

Location

Site 12106

Clarksville, Indiana, 47129, United States

Location

Site 12123

Merrillville, Indiana, 46410, United States

Location

Site 12105

Louisville, Kentucky, 40241, United States

Location

Site 12109

Las Vegas, Nevada, 89121, United States

Location

12127

Woodbury, New York, 11797, United States

Location

Site 12126

Portland, Oregon, 97210, United States

Location

Site 12125

Upper Saint Clair, Pennsylvania, 15241, United States

Location

Site 12103

College Station, Texas, 77845, United States

Location

Site 12118

El Paso, Texas, 79925, United States

Location

Site 12117

Houston, Texas, 77070, United States

Location

Related Links

• FDA Drug and Device Resources
• Office of Generic Drugs, Center for Drug Evaluation and Research. Draft Guidance on Tapinarof (PSG\_215272) \[Internet\]. Silver Spring, MD: U.S. Food and Drug Administration; 2023 \[cited 2024 May 10\].
• VTAMA (Tapinarof) cream, 1%, for topical use \[US Prescribing Information\] \[Internet\]. Long Beach, CA: Dermavant Sciences Inc.; 2023 \[cited 2024 May 16\].

MeSH Terms

Conditions

Skin Diseases; Skin Diseases, Papulosquamous

Condition Hierarchy (Ancestors)

Skin and Connective Tissue Diseases

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 16, 2024
• First Posted: December 19, 2024
• Study Start: December 17, 2024
• Primary Completion: October 7, 2025
• Study Completion: November 12, 2025
• Last Updated: December 17, 2025

Record last verified: 2025-12

Locations

US (26)